Texas House Bill HB3086

Texas 2025 - 89th Regular

• Filed: 2/20/25

Caption

Relating to requirements for pharmaceutical drug manufacturers to report prescription drug costs.

Impact

The bill's enactment could significantly alter how pharmaceutical companies operate within Texas, particularly in terms of pricing practices. By requiring detailed accounts of cost increases, the legislation intends to hold manufacturers accountable for price hikes, providing insight into the factors contributing to these changes. This transparency could empower state regulators and consumers, fostering informed discussions on drug affordability and accessibility.

Summary

House Bill 3086 aims to enhance transparency in the pharmaceutical industry by imposing reporting requirements on drug manufacturers regarding prescription drug costs. Under this bill, manufacturers are mandated to submit annual reports detailing the wholesale acquisition costs of FDA-approved drugs they sell within Texas. This includes a breakdown of any substantial price increases over a specified period, thus aiming to provide consumers and lawmakers with crucial information about drug pricing trends.

Contention

Despite its intentions, HB 3086 may face opposition from pharmaceutical companies that argue such reporting could place undue burdens on their operations. Critics may assert that the requirements for detailed disclosures could lead to less competitive pricing and potentially stifle innovation in drug development. Balancing the need for transparency with the operational realities of the pharmaceutical industry will likely be a point of contention as the bill progresses through the legislative process.

Texas Constitutional Statutes Affected

Health And Safety Code

• Chapter 441. Drug Cost Transparency
  • Section: 0051
  • Section: 0054
  • Section: 0102
  • Section: New Section
  • Section: 0053